PD-L1-话题@MedSci

#PD-L1#

309篇内容 | 6051人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1254896, encodeId=85ab125489621, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=喜讯！FDA授予默沙东免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）优先审查资格和突破性药物资格, objectType=article, longId=77041, objectId=3754e70412b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3754e70412b, replyNumber=0, likeNumber=62, createdTime=2016-09-10, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3754e70412b, moduleTitle=喜讯！FDA授予默沙东免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）优先审查资格和突破性药物资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3754e70412b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254895, encodeId=79c812548957e, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Cell Res：高福院士揭示PD-L1靶向性肿瘤治疗抗体的作用机制, objectType=article, longId=76606, objectId=6a9fe6606af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a9fe6606af, replyNumber=0, likeNumber=59, createdTime=2016-09-05, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a9fe6606af, moduleTitle=Cell Res：高福院士揭示PD-L1靶向性肿瘤治疗抗体的作用机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a9fe6606af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254894, encodeId=c3a31254894d9, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=雾里看花：PD-1/PD-L1抗体疗效评价的困惑, objectType=article, longId=74309, objectId=5773e430947, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5773e430947, replyNumber=0, likeNumber=64, createdTime=2016-08-04, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5773e430947, moduleTitle=雾里看花：PD-1/PD-L1抗体疗效评价的困惑, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5773e430947)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254893, encodeId=f0ee125489355, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Science：忘记PD-L1吧，破坏Cdk5也能促进抗肿瘤免疫反应, objectType=article, longId=73598, objectId=b0cde3598a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0cde3598a5, replyNumber=0, likeNumber=78, createdTime=2016-07-25, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0cde3598a5, moduleTitle=Science：忘记PD-L1吧，破坏Cdk5也能促进抗肿瘤免疫反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0cde3598a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254892, encodeId=b80112548922b, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=阿斯利康将携手Peregrine展开PD-L1抑制剂durvalumab联合用药研究, objectType=article, longId=70377, objectId=eb3fe037703, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb3fe037703, replyNumber=0, likeNumber=119, createdTime=2016-06-11, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb3fe037703, moduleTitle=阿斯利康将携手Peregrine展开PD-L1抑制剂durvalumab联合用药研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb3fe037703)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254891, encodeId=97c912548919c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=ASCO 2016：罗氏PD-L1免疫疗法Tecentriq一线治疗晚期膀胱癌显著缩小肿瘤体积, objectType=article, longId=70140, objectId=74afe0140e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74afe0140e6, replyNumber=0, likeNumber=72, createdTime=2016-06-08, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74afe0140e6, moduleTitle=ASCO 2016：罗氏PD-L1免疫疗法Tecentriq一线治疗晚期膀胱癌显著缩小肿瘤体积, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74afe0140e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254890, encodeId=771812548901f, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Nature：揭示出增加癌细胞抵抗免疫攻击的PD-L1基因变异, objectType=article, longId=69668, objectId=601c69668a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=601c69668a2, replyNumber=0, likeNumber=62, createdTime=2016-06-03, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=601c69668a2, moduleTitle=Nature：揭示出增加癌细胞抵抗免疫攻击的PD-L1基因变异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=601c69668a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254889, encodeId=a4f012548899c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=FDA批准PD-L1抑制剂——罗氏Tecentriq (atezolizumab)治疗尿路上皮癌, objectType=article, longId=68717, objectId=7e3c68e17a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e3c68e17a3, replyNumber=0, likeNumber=51, createdTime=2016-05-21, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e3c68e17a3, moduleTitle=FDA批准PD-L1抑制剂——罗氏Tecentriq (atezolizumab)治疗尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e3c68e17a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254888, encodeId=7ccc12548887c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=罗氏的PD-L1单抗获优先审评权，有望今年9月获批上市, objectType=article, longId=65151, objectId=432f65151fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=432f65151fc, replyNumber=0, likeNumber=57, createdTime=2016-03-23, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=432f65151fc, moduleTitle=罗氏的PD-L1单抗获优先审评权，有望今年9月获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=432f65151fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254887, encodeId=7269125488e48, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Lancet：PD-L1单抗Atezolizumab治疗转移性尿路上皮癌活性和耐受性良好, objectType=article, longId=64211, objectId=be266421184, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be266421184, replyNumber=0, likeNumber=55, createdTime=2016-03-08, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be266421184, moduleTitle=Lancet：PD-L1单抗Atezolizumab治疗转移性尿路上皮癌活性和耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be266421184)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254886, encodeId=1b4a12548860d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-L1免疫治疗药物avelumab牵手表观药物entinostat，联合治疗卵巢癌研究启动, objectType=article, longId=61803, objectId=98bd618032f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98bd618032f, replyNumber=0, likeNumber=35, createdTime=2016-01-09, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98bd618032f, moduleTitle=PD-L1免疫治疗药物avelumab牵手表观药物entinostat，联合治疗卵巢癌研究启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98bd618032f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254885, encodeId=d2e9125488579, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=SABC 2015：PD-L1抗体atezolizumab联合白蛋白紫杉醇治疗晚期三阴乳腺癌Ib期临床研究显示良好疗效与安全性（GP28328研究）, objectType=article, longId=60902, objectId=5d95609029e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d95609029e, replyNumber=0, likeNumber=65, createdTime=2015-12-22, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d95609029e, moduleTitle=SABC 2015：PD-L1抗体atezolizumab联合白蛋白紫杉醇治疗晚期三阴乳腺癌Ib期临床研究显示良好疗效与安全性（GP28328研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d95609029e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254884, encodeId=b05212548847c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=SABCS 2015：PD-L1免疫治疗在三阴乳腺癌（TNBC）治疗中显示潜力（JAVELIN研究）, objectType=article, longId=60901, objectId=a6706090118, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6706090118, replyNumber=0, likeNumber=69, createdTime=2015-12-22, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6706090118, moduleTitle=SABCS 2015：PD-L1免疫治疗在三阴乳腺癌（TNBC）治疗中显示潜力（JAVELIN研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6706090118)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254883, encodeId=b6601254883ea, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Lancet：Pembrolizumab能够显著延长PD-L1阳性晚期非小细胞肺癌患者的生存期, objectType=article, longId=60882, objectId=3e5560882c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e5560882c0, replyNumber=0, likeNumber=33, createdTime=2015-12-22, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e5560882c0, moduleTitle=Lancet：Pembrolizumab能够显著延长PD-L1阳性晚期非小细胞肺癌患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e5560882c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254882, encodeId=57491254882af, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=重磅! 美国前总统卡特脑部癌细胞消失，让世界再次聚焦PD-1/PD-L1重磅炸弹！, objectType=article, longId=60379, objectId=7a10603e94a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a10603e94a, replyNumber=0, likeNumber=57, createdTime=2015-12-09, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a10603e94a, moduleTitle=重磅! 美国前总统卡特脑部癌细胞消失，让世界再次聚焦PD-1/PD-L1重磅炸弹！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a10603e94a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254881, encodeId=065d125488126, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=ASCO 2015：膀胱尿路上皮癌抗PD-1及PD-L1抗体免疫治疗进展, objectType=article, longId=51776, objectId=99ee51e7685, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99ee51e7685, replyNumber=0, likeNumber=67, createdTime=2015-06-09, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99ee51e7685, moduleTitle=ASCO 2015：膀胱尿路上皮癌抗PD-1及PD-L1抗体免疫治疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99ee51e7685)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254880, encodeId=d0271254880af, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=MedImmune携手Juno！CAR-T疗法与PD-L1疗法联合将开启肿瘤免疫新篇章？！, objectType=article, longId=49896, objectId=41ff498968d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41ff498968d, replyNumber=0, likeNumber=69, createdTime=2015-04-29, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41ff498968d, moduleTitle=MedImmune携手Juno！CAR-T疗法与PD-L1疗法联合将开启肿瘤免疫新篇章？！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41ff498968d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254879, encodeId=aa2312548e986, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-L1类药物Pembrolizumab用于胃癌安全有效(KEYNOTE-012研究), objectType=article, longId=45645, objectId=3d624564589, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d624564589, replyNumber=0, likeNumber=84, createdTime=2015-01-18, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d624564589, moduleTitle=PD-L1类药物Pembrolizumab用于胃癌安全有效(KEYNOTE-012研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d624564589)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254878, encodeId=ffe112548e84d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-1/PD-L1领域竞争加剧：百时美联手2家日企开发免疫鸡尾酒Opdivo/mogamulizumab, objectType=article, longId=44001, objectId=f44c44001b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f44c44001b8, replyNumber=0, likeNumber=74, createdTime=2014-12-14, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f44c44001b8, moduleTitle=PD-1/PD-L1领域竞争加剧：百时美联手2家日企开发免疫鸡尾酒Opdivo/mogamulizumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f44c44001b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254877, encodeId=5c5212548e7a1, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=ESMO 2014：抗PD-L1联合贝伐单抗用于肾透明细胞癌安全和效果良好, objectType=article, longId=40875, objectId=3d03408e567, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d03408e567, replyNumber=0, likeNumber=68, createdTime=2014-10-04, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d03408e567, moduleTitle=ESMO 2014：抗PD-L1联合贝伐单抗用于肾透明细胞癌安全和效果良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d03408e567)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-L1

2020-05-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

喜讯！FDA授予默沙东免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）优先审查资格和突破性药物资格

2016-09-10

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Cell Res：高福院士揭示PD-L1靶向性肿瘤治疗抗体的作用机制

2016-09-05

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

雾里看花：PD-1/PD-L1抗体疗效评价的困惑

2016-08-04

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Science：忘记PD-L1吧，破坏Cdk5也能促进抗肿瘤免疫反应

2016-07-25

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

阿斯利康将携手Peregrine展开PD-L1抑制剂durvalumab联合用药研究

2016-06-11

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

ASCO 2016：罗氏PD-L1免疫疗法Tecentriq一线治疗晚期膀胱癌显著缩小肿瘤体积

2016-06-08

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Nature：揭示出增加癌细胞抵抗免疫攻击的PD-L1基因变异

2016-06-03

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

FDA批准PD-L1抑制剂——罗氏Tecentriq (atezolizumab)治疗尿路上皮癌

2016-05-21

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

罗氏的PD-L1单抗获优先审评权，有望今年9月获批上市

2016-03-23

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Lancet：PD-L1单抗Atezolizumab治疗转移性尿路上皮癌活性和耐受性良好

2016-03-08

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-L1免疫治疗药物avelumab牵手表观药物entinostat，联合治疗卵巢癌研究启动

2016-01-09

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

SABC 2015：PD-L1抗体atezolizumab联合白蛋白紫杉醇治疗晚期三阴乳腺癌Ib期临床研究显示良好疗效与安全性（GP28328研究）

2015-12-22

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

SABCS 2015：PD-L1免疫治疗在三阴乳腺癌（TNBC）治疗中显示潜力（JAVELIN研究）

2015-12-22

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Lancet：Pembrolizumab能够显著延长PD-L1阳性晚期非小细胞肺癌患者的生存期

2015-12-22

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

重磅! 美国前总统卡特脑部癌细胞消失，让世界再次聚焦PD-1/PD-L1重磅炸弹！

2015-12-09

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

ASCO 2015：膀胱尿路上皮癌抗PD-1及PD-L1抗体免疫治疗进展

2015-06-09

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

MedImmune携手Juno！CAR-T疗法与PD-L1疗法联合将开启肿瘤免疫新篇章？！

2015-04-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-L1类药物Pembrolizumab用于胃癌安全有效(KEYNOTE-012研究)

2015-01-18

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-1/PD-L1领域竞争加剧：百时美联手2家日企开发免疫鸡尾酒Opdivo/mogamulizumab

2014-12-14

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

ESMO 2014：抗PD-L1联合贝伐单抗用于肾透明细胞癌安全和效果良好

2014-10-04

科室
- - 订阅+
  - 更多科室
工具
服务